Growing community of inventors

San Diego, CA, United States of America

Charles A Glass

Average Co-Inventor Count = 4.00

ph-index = 7

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 116

Charles A GlassBrett E Crawford (15 patents)Charles A GlassJillian R Brown (14 patents)Charles A GlassRobin M Jackman (10 patents)Charles A GlassJim R Beitel (10 patents)Charles A GlassMark G Erlander (3 patents)Charles A GlassArne Huvar (3 patents)Charles A GlassAdrienne Dubin (3 patents)Charles A GlassJeffrey D Esko (1 patent)Charles A GlassJilllian R Brown (1 patent)Charles A GlassBryan Thacker (1 patent)Charles A GlassCharles A Glass (19 patents)Brett E CrawfordBrett E Crawford (15 patents)Jillian R BrownJillian R Brown (14 patents)Robin M JackmanRobin M Jackman (15 patents)Jim R BeitelJim R Beitel (10 patents)Mark G ErlanderMark G Erlander (54 patents)Arne HuvarArne Huvar (11 patents)Adrienne DubinAdrienne Dubin (8 patents)Jeffrey D EskoJeffrey D Esko (7 patents)Jilllian R BrownJilllian R Brown (1 patent)Bryan ThackerBryan Thacker (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Biomarin Pharmaceutical Inc. (13 from 135 patents)

2. Ortho-mcneil Pharmaceutical Corp. (3 from 363 patents)

3. Zacharon Pharmaceuticals, Inc. (2 from 2 patents)

4. Tega Therapeutics, Inc. (1 from 1 patent)


19 patents:

1. 11549000 - Cellular glycosaminoglycan compositions and methods of making and using

2. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

3. 10683530 - Detection of oligosaccharides

4. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

5. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

6. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA

7. 9796999 - Detection of oligosaccharides

8. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

9. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

10. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

11. 9029530 - Detection of oligosaccharides

12. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

13. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder

14. 8592140 - Detection of oligosaccharides

15. 8232073 - Quantification of non-reducing end glycan residual compounds

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/5/2025
Loading…